🇺🇸 FDA
Pipeline program

Resmetirom

MGL-3196-27

Phase 2 small_molecule active

Quick answer

Resmetirom for MASH - Metabolic Dysfunction-Associated Steatohepatitis is a Phase 2 program (small_molecule) at MADRIGAL PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
MADRIGAL PHARMACEUTICALS, INC.
Indication
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials